TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10235156

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11)
Number of subjects: 196

Group type: COMPARATOR
Intervention: RT only (64 Gy in 32 fractions over 6.4 weeks)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (in the nonrandomized part)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Combined modality therapy and RT only
Number of subjects: 196
Study: 8730980

Group type: EXPERIMENTAL
Intervention: Benzhexol (5 mg)
Number of subjects: 10
Study: 1959719

Group type: EXPERIMENTAL
Intervention: Sport activity (for asthmatic children)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No sport activity (control group)
Number of subjects: 30
Study: 6123287

Group type: EXPERIMENTAL
Intervention: Oxatomide (30 mg bid)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 31382998

Group type: COMPARATOR
Intervention: Computer-based cognitive rehabilitation (CCR) group: RehaCom cognitive rehabilitation once (30 min) a day, 3 days per week for 8 weeks.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with computer-based cognitive rehabilitation (EA-CCR) group: EA at Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), and Shenting (GV24) plus RehaCom cognitive rehabilitation once (30 min each) a day, 3 days per week for 8 weeks.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (CCR and EA-CCR)
Number of subjects: 36
Study: 30374316

Group type: EXPERIMENTAL
Intervention: SHARE (Spouses coping with the Head And neck Radiation Experience)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Medical Care (UMC)
Number of subjects: 60
Study: 26923888

Group type: EXPERIMENTAL
Intervention: Drainage group (received a drain at the end of operation)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (didn't receive a drain)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Drainage group
Number of subjects: 92
Study: 25631731

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 60
Study: 22507228

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21287904

Group type: EXPERIMENTAL
Intervention: Concurrent peer review visits
Number of subjects: 727

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 727
Study: 17613581

Group type: EXPERIMENTAL
Intervention: Intensive exercise group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Regular exercise group
Number of subjects: 75
Study: 16247343

Group type: EXPERIMENTAL
Intervention: Twist drill craniostomy (TDC) with closed-system drainage and suction reservoir
Number of subjects: 47

Group type: COMPARATOR
Intervention: Burr hole craniotomy (BHC) with subdural irrigation and closed drainage
Number of subjects: 47
Study: 12759845

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9527146

Group type: EXPERIMENTAL
Intervention: 24 g/day piracetam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 16.8 g/day piracetam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 9.6 g/day piracetam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7605861

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of famotidine 40 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gastrojet device delivering famotidine
Number of subjects: 12
Study: 2357194

Group type: EXPERIMENTAL
Intervention: MR Imaging using a 0.3 Tesla low field strength scanner
Number of subjects: 50
Study: 7246468

Group type: EXPERIMENTAL
Intervention: Hypnotic sensory imagery conditioning program (three-week duration, daily sessions with three conditioning images and self-hypnotic practice)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nontreatment control condition
Number of subjects: 60
Study: 31246097

Group type: EXPERIMENTAL
Intervention: Impella microaxillar mechanical support
Number of subjects: 15
Study: 31436643

Group type: EXPERIMENTAL
Intervention: mini‐SLET
Number of subjects: 92

Group type: COMPARATOR
Intervention: CAG
Number of subjects: 92
Study: 27856088

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1445
Study: 26491667

Group type: EXPERIMENTAL
Intervention: Print and post communications
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Email communications
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Telephone communications
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Text messaging
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Private Internet‐based social network messages
Number of subjects: 221
Study: 24450252

Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg daily
Number of subjects: 265

Group type: COMPARATOR
Intervention: Serenoa repens (SR) 320 mg daily
Number of subjects: 265

Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg daily + Serenoa repens (SR) 320 mg daily
Number of subjects: 265
Study: 21298443

Group type: EXPERIMENTAL
Intervention: Fibromyalgia subjects (younger and middle-aged)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fibromyalgia subjects (middle-aged)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Older fibromyalgia subjects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60
Study: 19807860

Group type: EXPERIMENTAL
Intervention: Well-being therapy
Number of subjects: 0
Study: 21404452

Group type: EXPERIMENTAL
Intervention: Continuous low-volume infusion of hydroxyethyl starch (HES) at a dose of 15 ml/kg/day
Number of subjects: 0
Study: 16188857

Group type: EXPERIMENTAL
Intervention: Home-based counselling by breastfeeding counsellors (n=68)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Home-based counselling by general childcare counsellors (n=67)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (n=69)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Breastfeeding counselled group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Infants exclusively breastfed for 6 months
Number of subjects: 204
Study: 12162272

Group type: EXPERIMENTAL
Intervention: Algorithm dosing of acenocoumarol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine dosing of acenocoumarol
Number of subjects: 103
Study: 10829375

Group type: EXPERIMENTAL
Intervention: Video-link instruction
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Telephone instruction
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Previous CPR training
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Direct observer instruction
Number of subjects: 4

Group type: COMPARATOR
Intervention: No instruction
Number of subjects: 4
Study: 8519713

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine concentrations of 0, 1:50,000, 1:200,000, 1:800,000, and 1:3,200,000
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with epinephrine concentrations of 0, 1:50,000, 1:200,000, 1:800,000, and 1:3,200,000
Number of subjects: 6

Group type: COMPARATOR
Intervention: Plain local anesthesia (without epinephrine)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epinephrine-induced vasoconstriction
Number of subjects: 6
Study: 2363117

Group type: EXPERIMENTAL
Intervention: i.v. low-dose aspirin
Number of subjects: 21

Group type: COMPARATOR
Intervention: i.v. isosorbide dinitrate and oral diltiazem
Number of subjects: 21
Study: 507079

Group type: EXPERIMENTAL
Intervention: 5-micrometers membrane filter
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.45-micrometers membrane filter
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no filter)
Number of subjects: 150
Study: 12587621

Group type: EXPERIMENTAL
Intervention: 5 microg/kg per day of intravenous rGCSF once daily for 3 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological serum (control group)
Number of subjects: 40
Study: 29775141

Group type: EXPERIMENTAL
Intervention: Structured group reminiscence therapy for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 0
Study: 26860786

Group type: EXPERIMENTAL
Intervention: Management training (90-min training session)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Control group (no management training)
Number of subjects: 434
Study: 24022378

Group type: EXPERIMENTAL
Intervention: Palivizumab prophylaxis
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 79
Study: 23478699

Group type: EXPERIMENTAL
Intervention: Lower protein diet (< 22% daily energy intake) + Resistance Training (RT)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Higher protein diet (> 22% daily energy intake) + Resistance Training (RT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lower protein diet (< 22% daily energy intake) + Habitual activity (Control)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Higher protein diet (> 22% daily energy intake) + Habitual activity (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Habitual activity (Control)
Number of subjects: 25
Study: 20034682

Group type: EXPERIMENTAL
Intervention: Injected activated macrophage suspension (AMS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 100
Study: 18929746

Group type: EXPERIMENTAL
Intervention: POR group (specialized rehabilitation sessions repeated after 90 days)
Number of subjects: 149

Group type: COMPARATOR
Intervention: PO group (limited rehabilitation)
Number of subjects: 149
Study: 15944095

Group type: EXPERIMENTAL
Intervention: DDD‐CLS pacing
Number of subjects: 17

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 17
Study: 12011547

Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting 5 s after injection
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Echovist-200 with VM for 5 s starting 5 s after injection
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting with the beginning of injection
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Echovist-300 with VM for 5 s starting 10 s after injection
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Echovist-200 with VM for 5 s starting with the beginning of injection
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: No VM
Number of subjects: 64
Study: 10424515

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction therapy (1.5 mg/kg/d for 3 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional immunosuppression alone (no induction therapy)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG) induction therapy
Number of subjects: 44
Study: 7772355

Group type: EXPERIMENTAL
Intervention: Fiberoptic laryngoscopy with atlanto‐occipital joint in the extended position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fiberoptic laryngoscopy with atlanto‐occipital joint in the neutral position
Number of subjects: 20
Study: 2181621

Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Plain naproxen tablets
Number of subjects: 12
Study: 159848

Group type: EXPERIMENTAL
Intervention: Intensive nursery care
Number of subjects: 143

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 143
Study: 31627773

Group type: EXPERIMENTAL
Intervention: Antimicrobial agents (specific agents not detailed)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 21
Study: 29307310

Group type: EXPERIMENTAL
Intervention: Decaffeinated green coffee bean extract (GCE) 400 mg twice per day for 8 weeks
Number of subjects: 0
Study: 27175447

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus plantarum L-137 (HK L-137) 10 mg daily for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo capsule daily for 12 weeks
Number of subjects: 39
Study: 25225951

Group type: EXPERIMENTAL
Intervention: EEN combined with rhubarb
Number of subjects: 126
Study: 21264685

Group type: EXPERIMENTAL
Intervention: Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM
Number of subjects: 31

Group type: COMPARATOR
Intervention: Plain cheese without probiotics
Number of subjects: 31
Study: 20380764

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Laser tonsillotomy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 26
Study: 17395053

Group type: EXPERIMENTAL
Intervention: Fluid Restriction (FR)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Free Fluid (FF)
Number of subjects: 67
Study: 15629834

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (4 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Subconjunctival saline (control)
Number of subjects: 57
Study: 11758798

Group type: EXPERIMENTAL
Intervention: Presence of a dog during mental stress
Number of subjects: 72

Group type: COMPARATOR
Intervention: No dog present during mental stress
Number of subjects: 72
Study: 9504571

Group type: COMPARATOR
Intervention: Control (35% of energy as fat)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low fat 1 (15% of energy as fat)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low fat 2 (50% of fat in the form of fish oil)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study: 8069055

Group type: EXPERIMENTAL
Intervention: Semiquantitative method (VDSG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Quantitative method (VDIM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Changes in spinal deformation (SDIM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VDIM for detecting vertebral fracture progression
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VDSG for diagnosing vertebra fractures
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VDIM for diagnosing vertebra fractures
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Baseline spinal deformation (SDIM and SDIG)
Number of subjects: 66
Study: 2923770

Group type: EXPERIMENTAL
Intervention: Sedation during regional conduction block without oxygen; 4 patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sedation during regional conduction block with oxygen (2 litre min‐1 via nasal catheter); 6 patients
Number of subjects: 10
Study: 30917927

Group type: EXPERIMENTAL
Intervention: BAY 85-8501 (1 mg once daily for 28 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 26992377

Group type: EXPERIMENTAL
Intervention: PCV
Number of subjects: 58

Group type: COMPARATOR
Intervention: VCV
Number of subjects: 58
Study: 25933488

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7000 μg retinol equivalents)
Number of subjects: 290

Group type: COMPARATOR
Intervention: β-carotene supplementation
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 290
Study: 22651957

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.2mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study: 22049673

Group type: EXPERIMENTAL
Intervention: CHIP intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 348
Study: 19928386

Group type: EXPERIMENTAL
Intervention: TIB restriction (90 minutes less than recorded during baseline)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control treatment (fixed sleep schedule consistent with average baseline, no TIB restriction)
Number of subjects: 42
Study: 16355285

Group type: EXPERIMENTAL
Intervention: Bumetanide (2 mg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15085035

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% with sodium bicarbonate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% with benzyl alcohol
Number of subjects: 47
Study: 11125713

Group type: COMPARATOR
Intervention: 0 mg glycyrrhizic acid/kg body weight
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1 mg glycyrrhizic acid/kg body weight
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2 mg glycyrrhizic acid/kg body weight
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 4 mg glycyrrhizic acid/kg body weight
Number of subjects: 39
Study: 9042977

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 500 mg b.d.
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg q.d.s.
Number of subjects: 236
Study: 7837158

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 167
Study: 3062082

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 250 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 500 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 750 mg/day
Number of subjects: 30
Study: 31802732

Group type: EXPERIMENTAL
Intervention: ePOCT (weight‐for‐age and mid‐upper arm circumference)
Number of subjects: 106

Group type: COMPARATOR
Intervention: ALMANACH (clinical signs of edema of both feet and visible severe wasting)
Number of subjects: 106
Study: 30316696

Group type: EXPERIMENTAL
Intervention: Dexketoprofen (1 mg kg–1 IV; administered every 8 hours)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Methadone (0.2 mg kg–1 IV; administered every 4 hours)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 38
Study: 26080652

Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 23021253

Group type: EXPERIMENTAL
Intervention: Elderly/passive priming
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Youthful/active priming
Number of subjects: 59
Study: 20206352

Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol sublingually plus 800 microg of misoprostol vaginally or orally, readministered after 24 hours if no response or incomplete abortion.
Number of subjects: 454
Study: 19034870

Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (EPO-alpha) to maintain hemoglobin levels in the range 12-14 g/dL, median final dose 2,000 IU/week.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no treatment unless hemoglobin decreased to 9.0 g/dL).
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (EPO-alpha) treatment group.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 95
Study: 17163135

Group type: EXPERIMENTAL
Intervention: Twinrix
Number of subjects: 200

Group type: COMPARATOR
Intervention: Havrix and Engerix-B
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Twinrix and monovalent vaccines
Number of subjects: 200
Study: 12019005

Group type: EXPERIMENTAL
Intervention: Palate re-repairs using the operating microscope with radical dissection and retropositioning of the velar muscles
Number of subjects: 85
Study: 9829116

Group type: EXPERIMENTAL
Intervention: Nidek KM‐800
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nikon NRK‐8000
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bausch and Lomb keratometer
Number of subjects: 30
Study: 7628128

Group type: EXPERIMENTAL
Intervention: Rescue angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 2082318

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Acetaminophen-codeine 600 mg plus 60 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 117953

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) stimulation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Insulin induced hypoglycaemia
Number of subjects: 35
Study: 7058581

Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve block with bupivacaine hydrochloride
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo nerve block
Number of subjects: 90
Study: 31492790

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 30053472

Group type: EXPERIMENTAL
Intervention: Automated SMS reminders containing information about diabetic retinopathy, sent 1 week and 3 days prior to scheduled eye appointments.
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Automated SMS reminders
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 233
Study: 27931291

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg once daily (n = 25)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No add-on (n = 28)
Number of subjects: 53
Study: 25096030

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 308

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 308
Study: 22257879

Group type: EXPERIMENTAL
Intervention: Experimental composites with filler contents of 80%, 76%, 70%, 60%, and 50% by weight
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Experimental composites with varying filler contents
Number of subjects: 25